Literature DB >> 25737338

HPLC-MS-MS Determination of ZCZ-011, A Novel Pharmacological Tool for Investigation of the Cannabinoid Receptor in Mouse Brain Using Clean Screen FASt™ Column Extraction.

Justin L Poklis1, Deborah J Clay2, Bogna M Ignatowska-Jankowska3, Chiara Zanato4, Ruth A Ross5, Iain R Greig4, Rehab A Abdullah3, Mohammed A Mustafa3, Aron H Lichtman3, Alphonse Poklis6.   

Abstract

A high-performance liquid chromatography tandem mass spectrometry method was developed for the detection and quantification of 6-methyl-3-(2-nitro-1-(thiophen-2-yl)propyl)-2-phenyl-1H-indole (ZCZ-011) using 2-phenylindole as the internal standard (ISTD). ZCZ-011 was synthesized as a possible positive allosteric modulator with the CB1 cannabinoid receptor. The analytical method employs a rapid extraction technique using Clean Screen FASt™ columns with a Positive Pressure Manifold. FASt™ columns were originally developed for urine drug analysis but we have successfully adapted them to the extraction of brain tissue. Chromatographic separation was performed on a Restek Allure Biphenyl 5 µ, 100 × 3.2 mm column (Bellefonte, PA). The mobile phase consisted of 1:9 deionized water with 10 mmol ammonium acetate and 0.1% formic acid-methanol. The following transition ions (m/z) were monitored for ZCZ-011: 363 > 207 and 363 > 110 and for the ISTD: 194 > 165 and 194 > 89. The FASt™ columns lowered and stabilized the ion suppression over the linear range of the assay (40-4,000 ng/g). The method was evaluated for recovery, ion suppression, accuracy/bias, intraday and interday precision, bench-top stability, freeze-thaw and post-preparative stability. The method was successfully applied to brain tissue from C57BL/6J mice that received intraperitoneal (i.p.) injections with 40 mg/kg of ZCZ-011 or vehicle.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25737338      PMCID: PMC4542657          DOI: 10.1093/jat/bkv015

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  10 in total

Review 1.  G protein-coupled receptor allosterism and complexing.

Authors:  Arthur Christopoulos; Terry Kenakin
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

2.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

Review 3.  Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

Authors:  Ruth A Ross
Journal:  Trends Pharmacol Sci       Date:  2007-11       Impact factor: 14.819

4.  Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology.

Authors: 
Journal:  J Anal Toxicol       Date:  2013-09       Impact factor: 3.367

5.  CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Authors:  Gemma L Baillie; James G Horswill; Sharon Anavi-Goffer; Patricia H Reggio; Daniele Bolognini; Mary E Abood; Sean McAllister; Phillip G Strange; Gary J Stephens; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2012-11-15       Impact factor: 4.436

6.  Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Authors:  Kwang H Ahn; Mariam M Mahmoud; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

7.  A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.

Authors:  Bogna M Ignatowska-Jankowska; Gemma L Baillie; Steven Kinsey; Molly Crowe; Sudeshna Ghosh; Robert A Owens; Imad M Damaj; Justin Poklis; Jenny L Wiley; Matteo Zanda; Chiara Zanato; Iain R Greig; Aron H Lichtman; Ruth A Ross
Journal:  Neuropsychopharmacology       Date:  2015-06-08       Impact factor: 7.853

8.  Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter.

Authors:  Hernán A Navarro; James L Howard; Gerald T Pollard; F Ivy Carroll
Journal:  Br J Pharmacol       Date:  2009-02-18       Impact factor: 8.739

9.  High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens.

Authors:  Justin L Poklis; Deborah J Clay; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-02-16       Impact factor: 3.367

Review 10.  The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

Authors:  Vincenzo Di Marzo
Journal:  Pharmacol Res       Date:  2009-03-04       Impact factor: 7.658

  10 in total
  3 in total

Review 1.  Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Authors:  Thuy Nguyen; Jun-Xu Li; Brian F Thomas; Jenny L Wiley; Terry P Kenakin; Yanan Zhang
Journal:  Med Res Rev       Date:  2016-11-23       Impact factor: 12.944

Review 2.  Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.

Authors:  Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

3.  A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.

Authors:  Bogna M Ignatowska-Jankowska; Gemma L Baillie; Steven Kinsey; Molly Crowe; Sudeshna Ghosh; Robert A Owens; Imad M Damaj; Justin Poklis; Jenny L Wiley; Matteo Zanda; Chiara Zanato; Iain R Greig; Aron H Lichtman; Ruth A Ross
Journal:  Neuropsychopharmacology       Date:  2015-06-08       Impact factor: 7.853

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.